2-amino-1-O-(4,4'-dimethoxytrityl)propane-1,3-diol | 154928-41-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-amino-1-O-(4,4'-dimethoxytrityl)propane-1,3-diol
• 英文别名: 2-amino-1-dimethoxytrityloxypropanol-3；1-O-(4,4'-Dimethoxytrityl)-2-aminopropan-3-ol；2-amino-3-[bis(4-methoxyphenyl)-phenylmethoxy]propan-1-ol
• CAS: 154928-41-3
• 化学式: C₂₄H₂₇NO₄
• 分子量: 393.483
• InChiKey: NSESDOQTZQNHLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  73.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-amino-1-O-(4,4'-dimethoxytrityl)propane-1,3-diol 在 吡啶 、 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 [2,2']Bipyridinyl-4,4'-dicarboxylic acid 4-{[2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-amide} 4'-({2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-1-hydroxymethyl-ethyl}-amide)
  参考文献：
  名称：

  Solid-phase synthesis of oligonucleotides containing a Bipyridine ligand at the 3′-3′ inversion of polarity site

  摘要：

  The preparation of a solid support useful for the synthesis of oligonucleotides with a 3'-3' inversion of polarity, via a linker containing a chelating molecule, namely 2,2'-bipyridine, is described. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00673-9
• 作为产物：
  描述：

  1-O-(4,4'-dimethoxytrityl)-2-trifluoroacetamidopropane-1,3-diol 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-amino-1-O-(4,4'-dimethoxytrityl)propane-1,3-diol
  参考文献：
  名称：

  糖修饰寡核苷酸的合成及杂交特性

  摘要：

  -制备苏氨酸衍生的无环核苷酸单体，并通过亚磷酰胺化学在预选位置掺入寡核苷酸。研究了这些修饰的寡核苷酸与相应的天然寡核苷酸的杂交特性，并进行了它们与丝氨醇修饰的寡核苷酸的 vis-a i-vis 比较。检查了修饰的寡聚体对人血清和蛇毒磷酸二酯酶 (SVPD) 中核酸酶的稳定性。介绍。± 当存在互补核苷酸序列时，寡核苷酸通过与单链核酸结合形成双螺旋的能力使其可用作诊断探针和分子遗传学工具 (1 ± 4)。因此，涉及这些核酸的生物过程可能会受到添加相应寡核苷酸的影响。修饰寡核苷酸的这一特殊特性使其可用于生物技术，最近还用于药物化学，以至于它们作为反义寡核苷酸的使用已被证明可在转录或翻译阶段调节（通常抑制）表达。因此，这些分子被视为新一代药物。然而，天然寡核苷酸存在一些局限性，即，对核酸酶的不稳定性、由中等链长寡核苷酸形成的双链体稳定性低，以及无法穿透亲脂性细胞膜。为了克服这些障碍，通常将修饰引入

  DOI：

  10.1002/1522-2675(20011219)84:12<3643::aid-hlca3643>3.0.co;2-q

文献信息

• Oligonucleotides comprising a non-phosphate backbone linkage
  申请人：Manoharan Muthiah

  公开号：US20060287260A1

  公开（公告）日：2006-12-21

  One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

  本发明的一个方面涉及在3'-位置用磷酰胺基团取代的核糖核苷。在某些实施例中，磷酰胺基团是烷基磷酰胺基团。本发明的另一个方面涉及包含至少一个非磷酸酯连接的双链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼基、酰胺和碳酸酯连接。在某些实施例中，非磷酸酯连接是磷酸酯连接。在某些实施例中，非磷酸酯连接仅出现在一条链中。在某些实施例中，非磷酸酯连接出现在两条链中。在某些实施例中，配体结合到包含双链寡核苷酸的寡核苷酸链中的一条链上。在某些实施例中，配体结合到包含双链寡核苷酸的寡核苷酸链中的两条链上。在某些实施例中，寡核苷酸链包含至少一个修饰的糖基团。本发明的另一个方面涉及包含至少一个非磷酸酯连接的单链寡核苷酸。代表性的非磷酸酯连接包括磷酸酯、羟胺、羟基肼基、酰胺和碳酸酯连接。在某些实施例中，非磷酸酯连接是磷酸酯连接。在某些实施例中，配体结合到寡核苷酸链上。在某些实施例中，寡核苷酸包含至少一个修饰的糖基团。
• Oligonucleotides comprising a C5-modified pyrimidine
  申请人：Manoharan Muthiah

  公开号：US20050288244A1

  公开（公告）日：2005-12-29

  One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.

  本发明的一个方面涉及包含至少一个配体的双链寡核苷酸。在某些实施例中，配体仅结合到构成双链寡核苷酸的两个核苷酸链中的一个。在某些实施例中，双链寡核苷酸的两个核苷酸链都独立地包含一个结合的配体。在某些实施例中，核苷酸链包含至少一个修饰的糖基。在某些实施例中，核苷酸链的一个或两个链中的磷酸酯键已被磷硫酸酯或磷二硫酸酯键替代。在一个首选实施例中，配体是胆固醇或5β-胆烷酸。本发明的另一个方面涉及包含至少一个配体的单链寡核苷酸。在某些实施例中，核苷酸包含至少一个修饰的糖基。在某些实施例中，核苷酸的磷酸酯键已被磷硫酸酯或磷二硫酸酯键替代。在一个首选实施例中，配体是胆固醇或5β-胆烷酸。配体改善了寡核苷酸的药代动力学性能。
• Modified oligonucleotides and compound that can be used for synthesizing same
  申请人：GUANGZHOU RIBOBIO CO., LTD.

  公开号：US20200369703A1

  公开（公告）日：2020-11-26

  The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleatides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

  本公开涉及生物医学技术领域，特别是涉及改良寡核苷酸和一种可用于合成相同的化合物以及一种修改寡核苷酸的方法。本公开还涉及使用改良寡核苷酸来预防和/或治疗与主体肝脏相关的疾病。
• Novel Reagents Utilizing A Serinol Scaffold For Labeling Synthetic Oligonucleotides
  申请人：Nelson Paul S.

  公开号：US20110077389A1

  公开（公告）日：2011-03-31

  Novel CE-phosphoramidites and CPG reagents have been synthesized from a serinol backbone. These reagents are useful to introduce functional groups or directly label oligonucleotides. The versatile serinol scaffold allows for labeling at any position (5′ or 3′ termini, or any internal position) during automated DNA synthesis. Multiple labels or functional groups can be achieved by repetitive coupling cycles. Optimal spacer arms and protected label moieties have been specially designed. Further, the natural 3-carbon atom internucleotide phosphate distance is retained when inserted internally.

  已经从丝氨醇骨架合成了新型CE-磷酰胺酰胺和CPG试剂。这些试剂可用于引入功能基团或直接标记寡核苷酸。多功能的丝氨醇支架允许在自动化DNA合成过程中的任何位置（5'端或3'端，或任何内部位置）进行标记。通过重复耦合循环可以实现多个标记或功能基团。优化的空间臂和保护标记基团已特别设计。此外，在内部插入时保留了自然的3碳原子间核苷酸磷酸酯距离。
• Use of oligonucleotides for inhibition of complement activation
  申请人：——

  公开号：US20020082227A1

  公开（公告）日：2002-06-27

  Methods for inhibiting complement activation using antisense oligonucleotides, preferably modified oligonucleotides. These compounds may be used therapeutically to treat undesirable complement-mediated events such as inflammation.

  使用反义寡核苷酸，最好是改良的寡核苷酸，来抑制补体激活的方法。这些化合物可用于治疗不良的补体介导事件，如炎症。